Loading...
Loading...
- Walgreens Boots Alliance Inc's WBA Q2 FY23 sales increased 3.3% Y/Y to $34.9 billion, up 4.5% on a constant currency basis, beating the consensus of $33.53 billion.
- Adjusted EPS reached $1.16, unchanged from Q1 FY23 and down 25.8% on a constant currency basis, reflecting a 26% headwind from lower COVID-19 vaccine and testing volumes, beating the consensus of $1.10.
- Adjusted operating income was $1.2 billion, down 25.4% on a constant currency basis, reflecting lower volumes of COVID-19 vaccinations and testing lapping the year-ago period's Omicron surge.
- Related: New York Governor, Attorney General Ask Three Pharmacy Operators' Commitment Over Abortion Drug Access.
- The company said it administered 2.4 million COVID-19 vaccinations in the quarter, down from around 11.8 million a year earlier.
- U.S. pharmacy comparable script volume growth of 3.5 percent, excluding immunizations, ahead of expectations and sequentially improving vs. Q1 FY23.
- Guidance: Walgreens maintains FY23 adjusted EPS of $4.45-$4.65 (consensus of $4.48) as strong core business growth is more than offset by lapping peak COVID-19 demand; pivoting to mid-twenties percent adjusted EPS growth in the second half of fiscal 2023 at the midpoint
- Price Action: WBA shares are up 1.18% at $33.33 during the premarket session on the last check Tuesday.
- Photo via Wikimedia Commons
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in